Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications

Progress in Brain Research

Volumn 184, Issue C, 2010, Pages 177-192

  Kuriakose, Renju ^a   Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biomarker; Compensation; Dopamine receptors; Dopamine transporter (DAT); Dopamine turnover; Dyskinesias; Fluctuations; Fluorodopa; Impulse control disorders; Positron emission tomography; Vesicular monoamine transporter type 2 (VMAT2)

Indexed keywords

6 FLUORODOPA F 18; DOPAMINE; LEVODOPA;

BOOK; BRAIN BLOOD FLOW; CORPUS STRIATUM; DISEASE COURSE; DOPAMINE RELEASE; DOWN REGULATION; DYSKINESIA; IMPULSE CONTROL DISORDER; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; ORBITAL CORTEX; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION;

EID: 77957227804     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)84009-9     Document Type: Chapter

References (129)

1. Ahlskog J.E. Slowing Parkinson's disease progression: Recent dopamine agonist trials. Neurology 2003, 60:381-389.
2. Albin R.L., Frey K.A. Initial agonist treatment of Parkinson disease: A critique. Neurology 2003, 60:390-394.
3. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends in Neuroscience 1989, 12:366-375.
4. Antonini A., Kazumata K., Feigin A., Mandel F., Dhawan V., Margouleff C., et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Movment Disorder 1998, 13:268-274.
5. Antonini A., Schwarz J., Oertel W.H., Pogarell O., Leenders K.L. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]raclopride. Movement Disorder 1997, 12:33-38.
6. Asanuma K., Tang C., Ma Y., Dhawan V., Mattis P., Edwards C., et al. Network modulation in the treatment of Parkinson's disease. Brain 2006, 129:2667-2678.
7. Au W.L., Adams J.R., Troiano A.R., Stoessl A.J. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Brain Research Molecular Brain Research 2005, 134:24-33.
8. Avanzi M., Baratti M., Cabrini S., Uber E., Brighetti G., Bonfa F. Prevalence of pathological gambling in patients with Parkinson's disease. Movement Disorder 2006, 21:2068-2072.
9. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of Neurological Science 1973, 20:415-455.
10. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. Journal of Neuroscience 2001, 21:6853-6861.
11. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature Medicine 2003, 9:762-767.
12. Bohnen N.I., Albin R.L., Koeppe R.A., Wernette K.A., Kilbourn M.R., Minoshima S., et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. Journal of Cerebral Blood Flow and Metabolism 2006, 26:1198-1212.
13. Boileau I., Rusjan P., Houle S., Wilkins D., Tong J., Selby P., et al. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?. Journal of Neuroscience 2008, 28:9850-9856.
14. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:3363-3367.
15. Braskie M.N., Wilcox C.E., Landau S.M., O'Neil J.P., Baker S.L., Madison C.M., et al. Relationship of striatal dopamine synthesis capacity to age and cognition. Journal of Neuroscience 2008, 28:14320-14328.
16. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:2569-2574.
17. Brooks D.J., Frey K.A., Marek K.L., Oakes D., Paty D., Prentice R., et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Experimental Neurology 2003, 184(Suppl 1):S68-S79.
18. Bruck A., Aalto S., Rauhala E., Bergman J., Marttila R., Rinne J.O. A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Movement Disorder 2009, 24:1009-1015.
19. Calne D.B., Lees A.J. Late progression of post-encephalitic Parkinson's syndrome. Canadian Journal of Neurological Sciences 1988, 15:135-138.
20. Calne D.B., Snow B.J., Lee C. Criteria for diagnosing Parkinson's disease. Annals of Neurology 1992, 32(Suppl):S125-S127.
21. Calne D.B., Zigmond M.J. Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. Archives of Neurology 1991, 48:361-363.
22. Cenci M.A., Lindgren H.S. Advances in understanding L-DOPA-induced dyskinesia. Current Opinion in Neurobiology 2007, 17:665-671.
23. Clarke C.E., Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002, 360:1767-1769.
24. Dalley J.W., Fryer T.D., Brichard L., Robinson E.S., Theobald D.E., Laane K., et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007, 315:1267-1270.
25. de Paulis T. The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain. Current Pharmaceutical Design 2003, 9:673-696.
26. de Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., et al. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54:S21-S23.
27. Doudet D.J., Chan G.L., Holden J.E., McGeer E.G., Aigner T.A., Wyatt R.J., et al. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998, 29:225-232.
28. Eckert T., Eidelberg D. Neuroimaging and therapeutics in movement disorders. NeuroRx 2005, 2:361-371.
29. Eckert T., Van Laere K., Tang C., Lewis D.E., Edwards C., Santens P., et al. Quantification of Parkinson's disease-related network expression with ECD SPECT. European Journal of Nuclear Medicine and Molecular Imaging 2007, 34:496-501.
30. Eidelberg D., Takikawa S., Moeller J.R., Dhawan V., Redington K., Chaly T., et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Annals of Neurology 1993, 33:518-527.
31. Evans A.H., Pavese N., Lawrence A.D., Tai Y.F., Appel S., Doder M., et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Annals of Neurology 2006, 59:852-858.
32. Evans A.H., Strafella A.P., Weintraub D., Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Movement Disorder 2009, 24:1561-1570.
33. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa-induced dyskinesias. Movement Disorder 2007, 22:1379-1389.
34. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later L-DOPA. Archives of Neurology 1999, 56:529-535.
35. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. New England Journal of Medicine 2004, 351:2498-2508.
36. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
37. Fine J., Duff J., Chen R., Chir B., Hutchison W., Lozano A.M., et al. Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. New England Journal of Medicine 2000, 342:1708-1714.
38. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New England Journal of Medicine 2001, 344:710-719.
39. Frey K.A., Koeppe R.A., Kilbourn M.R., Vander Borght T.M., Albin R.L., Gilman S., et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Annals of Neurology 1996, 40:873-884.
40. Fuente-Fernandez R., Lu J.Q., Sossi V., Jivan S., Schulzer M., Holden J.E., et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Annals of Neurology 2001, 49:298-303.
41. Fuente-Fernandez R., Pal P.K., Vingerhoets F.J., Kishore A., Schulzer M., Mak E.K., et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. Journal of Neural Transmission 2000, 107:49-57.
42. Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: Implications for dyskinesias. Brain 2004, 127:2747-2754.
43. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Medicine 2003, 9:589-595.
44. Golbe L.I. Young-onset Parkinson's disease: A clinical review. Neurology 1991, 41:168-173.
45. Grandas F., Galiano M.L., Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. Journal of Neurology 1999, 246:1127-1133.
46. Grosset K.A., Macphee G., Pal G., Stewart D., Watt A., Davie J., et al. Problematic gambling on dopamine agonists: Not such a rarity. Movement Disorder 2006, 21:2206-2208.
47. Hersch S.M., Yi H., Heilman C.J., Edwards R.H., Levey A.I. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. Journal of Comparative Neurology 1997, 388:211-227.
48. Hershey T., Black K.J., Stambuk M.K., Carl J.L., McGee-Minnich L.A., Perlmutter J.S. Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. Proceedings of the National Academy of Sciences USA 1998, 95:12016-12021.
49. Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenbach S., Jacobs A.H., et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Archives of Neurology 2005, 62:378-382.
50. Hirano S., Asanuma K., Ma Y., Tang C., Feigin A., Dhawan V., et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. Journal of Neuroscience 2008, 28:4201-4209.
51. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998, 51:S2-S9.
52. Huang C., Tang C., Feigin A., Lesser M., Ma Y., Pourfar M., et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007, 130:1834-1846.
53. Kaasinen V., Ruottinen H.M., Nagren K., Lehikoinen P., Oikonen V., Rinne J.O. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: A comparative PET study with [11C] raclopride and [11C]N-methylspiperone. Journal of Nuclear Medicine 2000, 41:65-70.
54. Karlsen K.H., Larsen J.P., Tandberg E., Maeland J.G. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1999, 66:431-435.
55. Kraytsberg Y., Kudryavtseva E., McKee A.C., Geula C., Kowall N.W., Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nature Genetics 2006, 38:518-520.
56. Kumar N., Van Gerpen J.A., Bower J.H., Ahlskog J.E. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Movement Disorder 2005, 20:342-344.
57. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology 2006, 59:459-466.
58. Lang A.E., Obeso J.A. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Annals of Neurology 2004, 55:761-765.
59. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Annals of Neurology 1999, 46:598-605.
60. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., et al. in vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Annals of Neurology 2000, 47:493-503.
61. Leyton M., Boileau I., Benkelfat C., Diksic M., Baker G., Dagher A. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: A PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 2002, 27:1027-1035.
62. Linazasoro G., Antonini A., Maguire R.P., Leenders K.L. Pharmacological and PET studies in patient's with Parkinson's disease and a short duration-motor response: Implications in the pathophysiology of motor complications. Journal of Neural Transmission 2004, 111:497-509.
63. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., et al. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study. Annals of Neurology 2002, 52:628-634.
64. Ma Y., Tang C., Spetsieris P.G., Dhawan V., Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: Test-retest reproducibility. Journal of Cerebral Blood Flow and Metabolism 2007, 27:597-605.
65. Marek K.L., Seibyl J.P., Zoghbi S.S., Zea-Ponce Y., Baldwin R.M., Fussell B., et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996, 46:231-237.
66. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurology 2008, 7:400-408.
67. McGeer P.L., Schwab C., Parent A., Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Annals of Neurology 2003, 54:599-604.
68. Miyasaki J.M., Al Hassan K., Lang A.E., Voon V. Punding prevalence in Parkinson's disease. Movement Disorder 2007, 22:1179-1181.
69. Morrish P.K., Rakshi J.S., Bailey D.L., Sawle G.V., Brooks D.J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. Journal of Neurology, Neurosurgery and Psychiatry 1998, 64:314-319.
70. Muchowski P.J. Protein misfolding, amyloid formation, and neurodegeneration: A critical role for molecular chaperones?. Neuron 2002, 35:9-12.
71. Nakamura T., Dhawan V., Chaly T., Fukuda M., Ma Y., Breeze R., et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Annals of Neurology 2001, 50:181-187.
72. Nandhagopal R., Kuramoto L., Schulzer M., Mak E., Cragg J., Lee C.S., et al. Longitudinal progression of sporadic Parkinson's disease: A multi-tracer positron emission tomography study. Brain 2009, 132:2970-2979.
73. Nandhagopal R., McKeown M.J., Stoessl A.J. Functional imaging in Parkinson disease. Neurology 2008, 70:1478-1488.
74. Nirenberg M.J., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. Journal of Neuroscience 1996, 16:436-447.
75. Nurmi E., Bergman J., Eskola O., Solin O., Hinkka S.M., Sonninen P., et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: A [18F]CFT PET study. Journal of Cerebral Blood Flow and Metabolism 2000, 20:1604-1609.
76. Nurmi E., Bergman J., Eskola O., Solin O., Vahlberg T., Sonninen P., et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse 2003, 48:109-115.
77. Nurmi E., Ruottinen H.M., Bergman J., Haaparanta M., Solin O., Sonninen P., et al. Rate of progression in Parkinson's disease: A 6-[18F]fluoro-L-dopa PET study. Movement Disorder 2001, 16(6):8-615.
78. Nurmi E., Ruottinen H.M., Kaasinen V., Bergman J., Haaparanta M., Solin O., et al. Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT. Annals of Neurology 2000, 47:804-808.
79. Obeso J.A., Merello M., Rodriguez-Oroz M.C., Marin C., Guridi J., Alvarez L. Levodopa-induced dyskinesias in Parkinson's disease. Handbook of Clinical Neurology 2007, 84:185-218.
80. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology 2003, 54:403-414.
81. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: Design and methods of the CALM-PD Study. Parkinson Study Group. Clinical Neuropharmacology 2000, 23:34-44. Parkinson study group.
82. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Journal of the American Medical Association 2002, 287:1653-1661. Parkinson study group.
83. Pate B.D., Kawamata T., Yamada T., McGeer E.G., Hewitt K.A., Snow B.J., et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Annals of Neurology 1993, 34:331-338.
84. Patlak C.S., Blasberg R.G., Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Journal of Cerebral Blood Flow and Metabolism 1983, 3:1-7.
85. Pavese N., Evans A.H., Tai Y.F., Hotton G., Brooks D.J., Lees A.J., et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: A PET study. Neurology 2006, 67:1612-1617.
86. Pezzella F.R., Colosimo C., Vanacore N., Di Rezze S., Chianese M., Fabbrini G., et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Movement Disorder 2005, 20:77-81.
87. Piccini P., Pavese N., Hagell P., Reimer J., Bjorklund A., Oertel W.H., et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 2005, 128:2977-2986.
88. Piccini P., Weeks R.A., Brooks D.J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Annals of Neurology 1997, 42:720-726.
89. Pinborg L.H., Videbaek C., Ziebell M., Mackeprang T., Friberg L., Rasmussen H., et al. [123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: Implications for the use of cerebellum as a reference region. Neuroimage 2007, 34:1450-1453.
90. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it?. Movement Disorder 2003, 18(Suppl 7):S43-S51.
91. Politis M.M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2010, 2:38-46.
92. Quinn N., Critchley P., Marsden C.D. Young onset Parkinson's disease. Movement Disorder 1987, 2:73-91.
93. Ravina B., Eidelberg D., Ahlskog J.E., Albin R.L., Brooks D.J., Carbon M., et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005, 64:208-215.
94. Rinne J.O., Laihinen A., Nagren K., Bergman J., Solin O., Haaparanta M., et al. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. Journal of Neuroscience Research 1990, 27:494-499.
95. Sanchez-Pernaute R., Jenkins B.G., Choi J.K., Iris Chen Y.C., Isacson O. in vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias. Neurobiology of Disease 2007, 27:220-227.
96. Schapira A.H., Gu M., Taanman J.W., Tabrizi S.J., Seaton T., Cleeter M., et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Annals of Neurology 1998, 44:S89-S98.
97. Schrag A., Jahanshahi M., Quinn N. What contributes to quality of life in patients with Parkinson's disease? Journal of Neurology. Neurosurgery and Psychiatry 2000, 69:308-312.
98. Schultz W. Reward signaling by dopamine neurons. Neuroscientist 2001, 7:293-302.
99. Schulzer M., Lee C.S., Mak E.K., Vingerhoets F.J., Calne D.B. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 1994, 117(Pt 3):509-516.
100. Seeman P., Guan H.C., Niznik H.B. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain. Synapse 1989, 3:96-97.
101. Seibyl J.P., Marek K.L., Quinlan D., Sheff K., Zoghbi S., Zea-Ponce Y., et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Annals of Neurology 1995, 38:589-598.
102. Seibyl J.P., Marek K., Sheff K., Baldwin R.M., Zoghbi S., Zea-Ponce Y., et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. Journal of Nuclear Medicine 1997, 38:1453-1459.
103. Snow B.J., Tooyama I., McGeer E.G., Yamada T., Calne D.B., Takahashi H., et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Annals of Neurology 1993, 34:324-330.
104. Sossi V., Doudet D.J., Holden J.E. A reversible tracer analysis approach to the study of effective dopamine turnover. Journal of Cerebral Blood Flow and Metabolism 2001, 21:469-476.
105. Sossi V., Fuente-Fernandez R., Holden J.E., Doudet D.J., McKenzie J., Stoessl A.J., et al. Increase in dopamine turnover occurs early in Parkinson's disease: Evidence from a new modeling approach to PET 18 F-fluorodopa data. Journal of Cerebral Blood Flow and Metabolism 2002, 22:232-239.
106. Sossi V., Fuente-Fernandez R., Holden J.E., Schulzer M., Ruth T.J., Stoessl J. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: Their relation to disease-compensatory mechanisms. Journal of Cerebral Blood Flow and Metabolism 2004, 24:869-876.
107. Sossi V., Fuente-Fernandez R., Schulzer M., Adams J., Stoessl J. Age-related differences in levodopa dynamics in Parkinson's: Implications for motor complications. Brain 2006, 129:1050-1058.
108. Sossi V., Fuente-Fernandez R., Schulzer M., Troiano A.R., Ruth T.J., Stoessl A.J. Dopamine transporter relation to dopamine turnover in Parkinson's disease: A positron emission tomography study. Annals of Neurology 2007, 62:468-474.
109. Steeves T.D., Miyasaki J., Zurowski M., Lang A.E., Pellecchia G., Van Eimeren T., et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: A [11C] raclopride PET study. Brain 2009, 132:1376-1385.
110. Stoessl A.J. Agonizing over dopaminergic replacement therapy - lessons from animal models of Parkinson's disease. Experimental Neurology 2003, 183:1-3.
111. Tatton W.G., Chalmers-Redman R., Brown D., Tatton N. Apoptosis in Parkinson's disease: Signals for neuronal degradation. Annals of Neurology 2003, 53(Suppl 3):S61-S70.
112. Tedroff J., Pedersen M., Aquilonius S.M., Hartvig P., Jacobsson G., Langstrom B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology 1996, 46:1430-1436.
113. Thobois S., Vingerhoets F., Fraix V., Xie-Brustolin J., Mollion H., Costes N., et al. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: A positron emission tomographic study. Archives of Neurology 2004, 61:1705-1709.
114. Tippmann-Peikert M., Park J.G., Boeve B.F., Shepard J.W., Silber M.H. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007, 68:301-303.
115. Tong J., Wilson A.A., Boileau I., Houle S., Kish S.J. Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 2008, 62:873-876.
116. Troiano A.R., Fuente-Fernandez R., Sossi V., Schulzer M., Mak E., Ruth T.J., et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009, 72:1211-1216.
117. Trost M., Su S., Su P., Yen R.F., Tseng H.M., Barnes A., et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage 2006, 31:301-307.
118. Turjanski N., Lees A.J., Brooks D.J. in vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997, 49:717-723.
119. Van Eimeren T., Ballanger B., Pellecchia G., Miyasaki J.M., Lang A.E., Strafella A.P. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: A trigger for pathological gambling in Parkinson's disease?. Neuropsychopharmacology 2009, 34:2758-2766.
120. van Kampen J.M., Stoessl A.J. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience 2003, 116:307-314.
121. Vander Borght T.M., Sima A.A., Kilbourn M.R., Desmond T.J., Kuhl D.E., Frey K.A. [3H]methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 1995, 68:955-962.
122. Vingerhoets F.J., Schulzer M., Calne D.B., Snow B.J. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Annals of Neurology 1997, 41:58-64.
123. Volkow N.D., Ding Y.S., Fowler J.S., Wang G.J., Logan J., Gatley S.J., et al. A new PET ligand for the dopamine transporter: Studies in the human brain. Journal of Nuclear Medicine 1995, 36:2162-2168.
124. Volkow N.D., Fowler J.S., Wang G.J., Logan J., Schlyer D., MacGregor R., et al. Decreased dopamine transporters with age in healthy human subjects. Annals of Neurology 1994, 36:237-239.
125. Voon V., Fernagut P.O., Wickens J., Baunez C., Rodriguez M., Pavon N., et al. Chronic dopaminergic stimulation in Parkinson's disease: From dyskinesias to impulse control disorders. Lancet Neurology 2009, 8:1140-1149.
126. Voon V., Hassan K., Zurowski M., de Souza M., Thomsen T., Fox S., et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006, 67:1254-1257.
127. Weintraub D., Siderowf A.D., Potenza M.N., Goveas J., Morales K.H., Duda J.E., et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Archives of Neurology 2006, 63:969-973.
128. 18 F-L829165 PET study [abstract]. Neurology 2002, 58:A488-A489.
129. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology 2003, 54:93-101.